October/November #191 : On the March - by Trenton Straube

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

Features

¡El SIDA Sí Da!

Cut to Fit

From the Editor

Rie y Llora

Feedback

Letters-October/November 2013

The POZ Q+A

Unidos Podemos

POZ Planet

Thank You, Sean Sasser

On the March

Get Lucky

Friend Request

Then There Were None

Why Should Gay and Bi Latino Men Get Tested?

Say What? Zombie Edition

Voices

Obamacare is Here

Care and Treatment

Reduced Dose of Sustiva Succeeds

New Ways to Beat Gonorrhea

Lower Bone Density Linked to Number of ARV Regimens

No Detectable HIV in Two Men After Stem Cell Transplants

WHO Revises Treatment Guidelines

Research Notes

Prevention: HIV Test May Help Improve Vaccines

Treatment: Normal Mortality Risk if Undetectable?

Cure: Cord Blood Transplant Aftermath

Concerns: Early Treatment in Developing World

POZ Heroes

A Test of Kindness

   
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

October / November 2013

On the March

by Trenton Straube

Two prevention tactics—PEP and PrEP—see on-the-ground action.

ACT UP protest Post-exposure prophylaxis, or PEP, is a way to prevent getting HIV after a possible exposure. It entails taking a regimen of three HIV meds for a month, starting no later than 72 hours after the incident. It’s been standard procedure since 2005, but when a gay man went to the emergency room at New York City’s Mount Sinai Hospital seeking PEP, confusion over its availability ensued. Once activist group ACT UP intervened, the man got the meds. On July 17, ACT UP protested outside the hospital to push the city and state health departments to promote the prevention pill and to ensure that all emergency health providers supply PEP. A similar protest August 15 at the health department also demanded the agency release accurate HIV data.

Pre-exposure prophylaxis, or PrEP
, is when HIV-negative people take Truvada (emtricitabine/tenofovir) daily to prevent getting the virus. The FDA approved Truvada as PrEP last summer, and now a University of California program is awarding $18 million to three teams studying PrEP—along with testing and linkage to care and treatment, or TLC+—in high-risk youths in Los Angeles, Long Beach, San Diego, Oakland and East Bay. Participants receive free meds along with counseling and health services. Meanwhile, the HIV Prevention Trials Network is launching the HPTN 073 study to explore whether black men who have sex with men—a population at high risk of HIV—are willing to use PrEP. The study will span three cities and include 225 men.

Search: Post-exposure prophylaxis, PEP, pre-exposure prophylaxis, PrEP, ACT UP, Truvada, HIV Prevention Trials Network, HPTN 073

Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


         

[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    chipper52
    Palm Springs
    California


    juliar33
    brooklyn
    New York


    OahuAJ
    Turlock
    California


    jap022964
    el dorado
    Arkansas
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Do you work with your doc to design your own treatment regimen?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.